Next Article in Journal
Usefulness of a Telemedicine Program in Refractory Older Congestive Heart Failure Patients
Next Article in Special Issue
Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
Previous Article in Journal
PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment
Previous Article in Special Issue
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Open AccessArticle

Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome

Department of Pharmacology, Toxicology, and Medicine, College of Medicine Al-Mustansiriyah University, P.O. Box 14132 Baghdad, Iraq
*
Author to whom correspondence should be addressed.
Diseases 2018, 6(1), 9; https://doi.org/10.3390/diseases6010009
Received: 5 December 2017 / Revised: 5 January 2018 / Accepted: 8 January 2018 / Published: 16 January 2018
Adipose tissue-derived serine protease inhibitor (vaspin), which has endocrine and local roles in atherosclerosis growth, is also synthesized by adipose tissue; it was found that vaspin was negatively correlated with blood pressure in obese patients, while vaspin levels were decreased in endothelial dysfunction. The aim of the present study was to determine rosuvastatin modulation effects on serum vaspin levels in acute coronary syndrome (ACS) with class I obesity. A total number of seventy patients with acute coronary syndrome previously and currently treated with rosuvastatin was compared to 40 patients with IHD not treated by rosuvastatin as a control. Vaspin serum levels were higher in rosuvastatin-treated patients with acute coronary syndrome compared to the patients with acute coronary syndrome not treated by rosuvastatin, p < 0.01. Additionally, in the rosuvastatin-treated group, patients with STEMI showed higher vaspin serum levels compared to NSTEMI p < 0.01. Conclusion: Rosuvastatin significantly increases vaspin serum levels in acute coronary syndrome. View Full-Text
Keywords: vaspin; acute coronary syndrome; NSTEMI; STEMI vaspin; acute coronary syndrome; NSTEMI; STEMI
Show Figures

Figure 1

MDPI and ACS Style

Al-kuraishy, H.M.; Al-Gareeb, A.I.; Al-Buhadilly, A.K. Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Diseases 2018, 6, 9.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop